Containment Development Generic Pharmaceutical Trials 
The Pharma Data
MAY 8, 2021
Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. nAMD accounts for 10% of all age-related macular degeneration cases, but is responsible for 90% of AMD-related blindness 2 ,” said Florian Bieber, Global Head of Biopharmaceuticals Development, Sandoz.
The Pharma Data
MAY 2, 2021
Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. The initiation of this study marks an important milestone in the development of our biosimilar aflibercept. Aflibercept is a key treatment in ophthalmology. Disclaimer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma in Brief
DECEMBER 3, 2023
For example, in 1993, the Federal Court of Appeal ( FCA ) held that section 6 proceedings would run as applications, meaning that discovery was generally unavailable and cases would be heard on only a written record, without a trial. [3] The first trial was decided in April 2020 (discussed here ). Where we are now Staying power.
The Pharma Data
MAY 15, 2023
The Sandoz Board of Directors will have 10 members in total and 3 sub-committees: a Science, Innovation & Development Committee, a Human Capital & ESG Committee and an Audit, Risk & Compliance Committee. She is also a board member at BBI Solutions, a UK based diagnostic reagents and a Novo Holdings company.
The Pharma Data
MAY 18, 2021
Sandoz is the global leader in generic antibiotics and operates the only vertically-integrated antibiotic network left in Europe, despite fierce competition from Asia. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.
XTalks
AUGUST 2, 2023
is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.
The Pharma Data
DECEMBER 23, 2020
24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .
Expert insights. Personalized for you.
52 
Let's personalize your content